Costco Wholesale Corporation (COST) has recently garnered attention in the investment community after Chuck Cerankosky of Northcoast Research upgraded the stock to a “Buy” o. With a current trading ...
Summary • Biohaven Ltd. shares dropped 16.6% to $9.02 in after-hours trading following a Phase 2 study update on BHV-7000 for major depressive disorder.• The clinical update revealed challenges ...
Summary • Elong Power Holding Limited’s stock fell 8.6% in after-hours trading to $0.1305 following a close at $0.1427.• The company announced a 16-for-1 reverse stock split during a special ...
Summary • SOBR Safe, Inc. shares fell 17% in after-hours trading to $1.96 following a $2 million private placement announcement.• The company plans to issue 1,290,324 shares at $1.55 per share, which ...
Summary • Nuvve Holding Corp. shares rose 5.6% in after-hours trading following a strategic agreement.• The company signed a non-binding MOU with E&B Renewables to deploy Battery Energy Storage ...
Summary • Webus International Limited (WETO) fell 7.5% to $0.90 in after-hours trading despite announcing expansion into the U.S. outdoor smart equipment and robotics market.• The stock’s trading ...
Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• Yartemlea is the first therapy targeting hematopoietic stem cell ...
Summary • Lexaria Bioscience Corp. (LEXX) shares fell 9.1% to $0.5633 despite recent successful clinical study results.• The company reported a significant reduction in side effects from its Phase 1b ...
Summary • Rezolute, Inc. shares rose 13.6% to $2.75 amidst ongoing investigations and legal concerns following a significant trial failure.• The stock has seen increased trading volume, with a notable ...
Summary • SRx Health Solutions Inc. shares rose 16.5% to $0.2561 amid investor interest, despite the absence of a clear catalyst for the price increase.• The company expanded its risk-intelligence ...
Summary • Can-Fite BioPharma shares fell 19.9% to $0.1926 following a reverse stock split announcement.• The company will implement a 1-for-3,000 reverse split effective January 2, 2026, approved by ...
Summary • Edgewise Therapeutics’ stock (EWTX) rose 15.6% to $25.13 amid positive clinical trial news.• Completion of Phase 2 trials for EDG-7500 and favorable safety results enhance investor sentiment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback